Steve Schonfeld’s AnaptysBio ANAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$5.57M Buy
+110,773
New +$6.27M 0.02% 653
2026
Q1
– Sell
-24,431
Closed -$1.18M – 2186
2025
Q4
$1.18M Buy
+24,431
New +$952K 0.01% 1062
2024
Q4
– Sell
-6,351
Closed -$213K – 1980
2024
Q3
$213K Sell
6,351
-165,242
-96% -$5.64M ﹤0.01% 1794
2024
Q2
$4.3M Buy
+171,593
New +$4M 0.03% 603
2022
Q4
– Sell
-25,465
Closed -$650K – 2568
2022
Q3
$650K Buy
+25,465
New +$597K 0.01% 1562
2019
Q2
– Sell
-91,600
Closed -$6.69M – 974
2019
Q1
$6.69M Buy
91,600
+31,900
+53% +$2.2M 0.23% 118
2018
Q4
$3.81M Buy
59,700
+20,000
+50% +$1.49M 0.15% 196
2018
Q3
$3.96M Buy
39,700
+34,000
+596% +$2.82M 0.18% 166
2018
Q2
$405K Sell
5,700
-1,275
-18% -$107K 0.02% 576
2018
Q1
$726K Buy
+6,975
New +$786K 0.05% 395

Other funds holding ANAB

Steve Schonfeld's ANAB Position: Q3 2026 in Review

Steve Schonfeld opened a new position in AnaptysBio (ANAB) in Q3 2026: 110,773 shares worth $5.57M. The stake represents 0.02% of the portfolio and ranks #653 among its holdings. This is a return to the name: Steve Schonfeld previously reported a position in ANAB as recently as Q4 2025.

Steve Schonfeld first reported a position in ANAB in Q1 2018 and has held it in 10 quarters since. The position peaked at $6.69M in Q1 2019. 229 funds tracked by Wall St. Rank hold ANAB as of Q3 2026.

  • Steve Schonfeld held 110,773 shares of AnaptysBio worth $5.57M as of Q3 2026.
  • AnaptysBio was a new Steve Schonfeld position in Q3 2026.
  • AnaptysBio made up 0.02% of Steve Schonfeld's portfolio in Q3 2026, its #653 holding.
  • Steve Schonfeld first reported a position in AnaptysBio in Q1 2018 and has held it in 10 quarters since.
  • Steve Schonfeld's AnaptysBio position peaked at $6.69M in Q1 2019.
  • 229 funds tracked by Wall St. Rank held AnaptysBio as of Q3 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.